Adults with IgA nephropathy who took Trutakna (atacicept-vymj) lost an average of 0.6 units of estimated kidney function per year over two years, while those on placebo lost 5.6 units per year, Vera Therapeutics reported on Sept. 15. The results come from the final efficacy analysis of the 428-patient ORIGIN 3 trial.
Update Note: This article reports new two-year kidney function results for Trutakna following MedicalDaily's earlier coverage of the drug's July approval. The latest verified information comes from a Vera Therapeutics announcement dated Sept. 15, 2026, and reflects topline data from the ORIGIN 3 final efficacy analysis.